Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Clinical Laserthermia Systems AB    CLSRB   SE0002756130

CLINICAL LASERTHERMIA SYSTEMS AB

(CLSRB)
  Report  
SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news
The feature you requested does not exist. However, we suggest the following feature:

Clinical Laserthermia : CLS Releases White Paper Regarding its imILT Immuno-Stimulating Method for Treating Cancer Tumours at ECIO 2019 Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/09/2019 | 04:54am EDT

(GlobeNewswire) - Clinical Laserthermia Systems AB (publ) (CLS) today released a technical white paper regarding the companys imILT immuno-stimulating method for treating cancer tumours at the European Conference on Interventional Oncology (ECIO) in Amsterdam, the Netherlands this April 8-11, 2019. The white papers technical materials include pre-clinical and clinical studies, treatment method developments, and data on safety and usability topics. The full imILT White Paper is available here.

Our imILT white paper includes data and compiled information in a format primarily directed to doctors, says Lars-Erik Eriksson, CEO at CLS. It highlights our research behind the treatment methods and the promising survival results shown in our clinical studies regarding the imILT treatment of pancreatic cancer. Our goal and expectation is that doctors will find our latest comprehensive information to be interesting and relevant.

CLS is a Gold Sponsor at ECIO 2019 and will be featured during a one-hour symposium focusing on imILT, the method in an immunological context and the studies carried out on pancreatic cancer indication. The symposium is held in collaboration with Dr. Belarmino Gonalves, Professor Olivier Turrini, Professor Gunnar Hedlund, and the co-founder, Professor Karl-Gran Tranberg, who will all talk about different aspects of imILT. The symposium will take place on Tuesday, April 9th and is chaired by Professor Andreas Mahnken.

ECIO was held for the first time in 2008 and became an annual conference in 2012 aimed for experts in interventional oncology, i.e. interventional radiology, focusing on future options for cancer treatment. These treatments are typically less invasive than traditional surgery and are performed by image guidance such as computer tomography (CT) or magnetic resonance imaging (MRI) or ultrasound (US). CLS is a member of the CIRSE (Cardiovascular and Interventional Radiological Society of Europe) organization behind the conference. Last year`s ECIO in Vienna had more than 1,400 participants, which is a record for the event.

More information is available on ECIO at www.ecio.org

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.

Company Contact:Lars-Erik Eriksson, CEO Clinical Laserthermia Systems AB (publ)Tel: +46 (0)702 90 33 00 E-mail:lee@clinicallaser.se

Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immuno-stimulating interstitial laser thermotherapy, imILT. The company, which is headquartered in Lund Sweden and has a subsidiary in Berlin, Germany and Boston, MA, USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser: Vstra Hamnen Corporate Finance AB, Tel: +46 40200250 E-mail:ca@vhcorp.se. Further information is available on www.clinicallaser.se

(c) 2019 TehranTimes. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CLINICAL LASERTHERMIA SYST
04/09CLINICAL LASERTHERMIA : CLS Releases White Paper Regarding its imILT Immuno-Stim..
AQ
04/08CLINICAL LASERTHERMIA : CLS Releases White Paper Regarding its imILT® Immuno-Sti..
AQ
03/26CLINICAL LASERTHERMIA : CLS Presents MRI-Guided, Laser Ablation Solutions for Pr..
AQ
03/05CLINICAL LASERTHERMIA : New article on FLA treatment of prostate cancer publishe..
AQ
02/21CLINICAL LASERTHERMIA : CLS participates with hands-on workshop and symposium at..
AQ
01/08CLS signs agreement with Siemens Healthineers to secure optimal interfacing t..
AQ
2018CLINICAL LASERTHERMIA : CLS report to EU Horizon2020 shows continued promising s..
AQ
2018CLINICAL LASERTHERMIA : MRI Interventions and Clinical Laserthermia Systems (CLS..
AQ
2018CLINICAL LASERTHERMIA : MRI Interventions and Clinical Laserthermia Systems (CLS..
AQ
2018CLINICAL LASERTHERMIA : CLS Signs Exclusive Distribution Agreement with MRI Inte..
AQ
More news
Financials (SEK)
Sales 2019 9,25 M
EBIT 2019 -36,9 M
Net income 2019 -34,0 M
Debt 2019 2,00 M
Yield 2019 -
P/E ratio 2019 -
P/E ratio 2020
EV / Sales 2019 36,6x
EV / Sales 2020 8,20x
Capitalization 337 M
Chart CLINICAL LASERTHERMIA SYSTEMS AB
Duration : Period :
Clinical Laserthermia Systems AB Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Lars-Erik Thomas Eriksson Chief Executive Officer & Director
Hans von Celsing Executive Chairman
Stephan Carl-Otto Dymling Chief Technical Officer
Mats Ekelund Chief Medical Officer
Karl-Göran Tranberg Director & Senior Medical Advisor
Sector and Competitors
1st jan.Capitalization (M$)
CLINICAL LASERTHERMIA SYSTEMS AB36
THERMO FISHER SCIENTIFIC15.07%102 995
DANAHER CORPORATION24.30%89 376
INTUITIVE SURGICAL9.62%60 565
BOSTON SCIENTIFIC CORPORATION-1.22%48 542
ILLUMINA6.24%46 847